The details of the efficacy analysis are shown in Table 4. The incidence of MACE in the efficacy analysis was 1.9% during prasugrel treatment, and 3.1% up to the end of the observation period. Cardiovascular death was the most common MACE, occurring in 13 patients with an incidence of 1.8% at the end of the study period. Of these, eight patients had severe cardiovascular disease (Killip Class IV). The incidence of all-cause death was 1.1% during prasugrel treatment and 2.2% up to the end of the study. Cardiovascular death accounted for approximately three-fourths of all-cause death.Table 4Incidence of cardiovascular eventsEfficacy outcomesCumulative incidence (%) N = 732On treatmentUntil the end of the observation period (EAS)MACE14 (1.9)23 (3.1) CV death6 (0.8)13 (1.8) Non-fatal MI5 (0.7)5 (0.7) Non-fatal ischemic stroke3 (0.4)5 (0.7)All-cause death8 (1.1)17 (2.3)Non-fatal stroke3 (0.4)6 (0.8)Readmission due to angina pectoris4 (0.5)8 (1.1)Revascularization10 (1.4)16 (2.2)Stent thrombosis2 (0.3)5 (0.7) EAS efficacy analysis set, MACE major adverse cardiovascular events, CV cardiovascular, MI myocardial infarction